Sevabertinib is an oral, reversible, small-molecule tyrosine kinase inhibitor (TKI) designed to target HER2-activating ...

Novo Nordisk has raised its full-year 2026 outlook for adjusted sales and operating profit following a stronger-than-expected ...

Alembic Pharmaceuticals Limited reported a massive 81% year-on-year surge in consolidated profit after tax (PAT) to Rs. 335 ...

Updated Phase 1 TRIgnite-1 data includes longer follow-up and early dose-expansion results for heavily pretreated multiple ...

The expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US ...

Bright Minds Biosciences has suffered a regulatory setback after the US Food and Drug Administration (FDA) placed a partial ...

BASF is stepping up its push into next-generation beauty and skincare innovation with the launch of Lincare, a naturally ...

The project will add 160,000 litres of manufacturing capacity, increasing the facility's total capacity by approximately 25% ...

Zydus Lifesciences Limited has officially completed its acquisition of the Active Pharmaceutical Ingredient (API) business of ...

International operations emerged as the biggest growth driver, posting a 34.5% increase in revenue to Rs 16,652 million ...

Merck is exiting its contract development and manufacturing organization (CDMO) business, agreeing to sell the operations to ...

While Pharmaceuticals gathered momentum, Crop Science and Consumer Health continued to perform in line with their respective ...